Korsuva is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney
disease in adult patients on haemodialysis (see section 5.1).

Korsuva should be restricted for in-centre haemodialysis use only.

Korsuva is intended for use by healthcare professionals experienced in the diagnosis and treatment of
conditions for which difelikefalin is indicated. Causes of pruritus other than chronic kidney disease
should be excluded before initiating treatment with difelikefalin.

Posology

Difelikefalin is administered 3 times per week by intravenous bolus injection into the venous line of
the dialysis circuit at the end of the haemodialysis treatment during rinse-back or after rinse-back.

The recommended dose of difelikefalin is 0.5 micrograms/kg dry body weight (i.e., the target
postdialysis weight). The total dose volume (mL) required from the vial should be calculated as
follows: 0.01 × dry body weight (kg), rounded to the nearest tenth (0.1 mL). For patients with a dry
body weight equal to or above 195 kg the recommended dose is 100 micrograms (2 mL). Injection
volumes are detailed in the table below:

1 More than 1 vial may be necessary if an injection volume of more than 1 mL is required.

An effect of difelikefalin in reducing pruritus is expected after 2-3 weeks of treatment.

Missed doses

If a regularly scheduled haemodialysis treatment is missed, Korsuva should be administered at the
next haemodialysis treatment at the same dose.

Extra treatment

If a 4th haemodialysis treatment is performed in a week, Korsuva should be administered at
the end of the haemodialysis per the recommended dose. No more than 4 doses per week
should be administered even if the number of haemodialysis treatments in a week exceeds 4. A
4th dose of Korsuva is unlikely to lead to accumulation of difelikefalin that would be of
concern for safety, as the majority of remaining difelikefalin from the previous treatment will
be cleared by haemodialysis (see sections 4.9 and 5.2). However, safety and efficacy of a 4th
dose has not been fully established due to insufficient data.

Patients with incomplete haemodialysis treatment

For haemodialysis treatments less than 1 hour, administration of difelikefalin should be withheld until
the next haemodialysis session.
Following administration of difelikefalin in haemodialysis subjects, up to 70% is eliminated from the
body prior to the next haemodialysis session (see sections 4.9 and 5.2). Difelikefalin plasma level
remaining at the time of the next haemodialysis is reduced by about 40-50% within one hour of
haemodialysis.

Patients with hepatic impairment

No dose adjustment is required for patients with mild or moderate hepatic impairment (see section
5.2). Difelikefalin has not been studied in subjects with severe hepatic impairment (National Cancer
Institute (NCI) Organ Dysfunction Working Group (ODWG)) and is therefore not recommended for
use in this patient population.

Elderly population (≥ 65 years of age)

Dosing recommendations for elderly patients are the same as for adult patients.

Paediatric population

The safety and efficacy of difelikefalin in children aged 0-17 years has not yet been established.
No data are available.

Method of administration

Korsuva should not be diluted and should not be mixed with other medicinal products.

Difelikefalin is removed by the dialyzer membrane and must be administered after blood is no longer
circulating through the dialyzer. Difelikefalin is administered 3 times per week by intravenous bolus
injection into the venous line of the dialysis circuit at the end of the haemodialysis treatment during
rinse-back or after rinse-back.
When given after rinse-back, at least 10 mL of sodium chloride 9 mg/mL (0.9%) solution for injection
rinse-back volume should be administered after injection of Korsuva. If the dose is given during
rinse-back, no additional sodium chloride 9 mg/mL (0.9%) solution for injection is needed to flush the
line.

Hyperkalaemia

Hyperkalaemia frequently occurs in chronic kidney disease patients on haemodialysis. In the placebocontrolled
clinical studies a numerically higher rate of adverse events of hyperkalaemia was reported
for the difelikefalin treated patients (4.7%; 20 / 424 patients) compared to placebo (3.5%; 15 / 424
patients). No causal relationship was established. Frequent monitoring of potassium levels is
recommended.

Cardiac failure and atrial fibrillation

Difelikefalin has not been studied in patients with New York Heart Association class IV heart failure.
In the pivotal clinical studies a small numerical imbalance of cardiac failure and atrial fibrillation
events was observed in the difelikefalin treated patients compared to placebo, in particular among
patients with a medical history of atrial fibrillation who discontinued or missed their atrial fibrillation
treatment. No causal relationship was established.

Patients with impaired blood-brain barrier

Difelikefalin is a peripherally acting kappa opioid receptor agonist with restricted access to the central
nervous system (CNS). The blood-brain barrier (BBB) integrity is important for minimizing
difelikefalin uptake into the CNS (see section 5.1). Patients with clinically important disruptions to the
BBB (e.g., primary brain malignancies, CNS metastases or other inflammatory conditions, active
multiple sclerosis, advanced Alzheimer’s disease) may be at risk for difelikefalin entry into the CNS.
Korsuva should be prescribed with caution in such patients taking into account their individual
benefit-risk balance with observation for potential CNS effects.

Dizziness and somnolence

Dizziness and somnolence have occurred in patients taking difelikefalin and may subside over time
with continued treatment (see section 4.8). Concomitant use of sedating antihistamines, opioid
analgesics or other CNS depressants may increase the likelihood of these adverse reactions and should
be used with caution during treatment with difelikefalin (see section 4.5).
Compared to placebo, the incidence of somnolence was higher in difelikefalin treated subjects
65 years of age and older (7.0%) than in difelikefalin treated subjects less than 65 years of age (2.8%).

Excipients with known effect

This medicinal product contains less than 1 mmol sodium per vial, that is to say essentially sodium-free.

No clinical interaction studies have been performed. Difelikefalin does not inhibit or induce CYP450
enzymes and is not a substrate of CYP450 enzymes. It is not an inhibitor of glucuronidating enzymes
either. Difelikefalin is not a substrate or an inhibitor of human transporters (see section 5.2).
Therefore, interactions of difelikefalin with other medicinal products are unlikely.
Concurrent administration of medicinal products such as sedating antihistamines, opioid analgesics or
other CNS depressants (e.g., clonidine, ondansetron, gabapentin, pregabalin, zolpidem, alprazolam,
sertraline, trazodone) may increase the likelihood of dizziness and somnolence (see section 4.4).

Pregnancy

There are no or limited amount of data from the use of difelikefalin in pregnant women.
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity
(see section 5.3).

As a precautionary measure, it is preferable to avoid the use of Korsuva during pregnancy.

Breast-feeding
It is unknown whether difelikefalin is excreted in human breast milk.

A risk to the newborns/infants cannot be excluded.

A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from
Korsuva therapy taking into account the benefit of breast-feeding for the child and the benefit of
therapy for the woman.

Animal studies have shown excretion of difelikefalin in breast milk.

Fertility
There are no data on the effect of difelikefalin on fertility in humans. In rat studies with difelikefalin,
there was no effect on fertility (see section 5.3).

Korsuva has minor influence on the ability to drive and use machines.
Somnolence and/or dizziness have been reported in patients receiving difelikefalin (see section 4.8).
Patients should be cautioned about driving or operating hazardous machinery until the effect of
difelikefalin on the patient’s ability to drive or operate machinery is known. Somnolence occurred
within the first 3 weeks of treatment and tended to subside with continued dosing. Dizziness occurred
within the first 9 weeks of treatment and was generally transient.

Summary of the safety profile

In placebo controlled and uncontrolled phase 3 clinical studies, approximately 6.6% of the patients
experienced at least one adverse reaction during difelikefalin treatment. The most common adverse
reactions were somnolence (1.1%), dizziness (0.9%), paraesthesia (including hypoesthesia,
paraesthesia oral and hypoesthesia oral) (1.1%), headache (0.6%), nausea (0.7%), vomiting (0.7%),
diarrhoea (0.2%) and mental status changes (including confusional state) (0.3%). Most of these
events were mild or moderate in severity, did not lead to deleterious consequences, and resolved
with ongoing therapy. No event was serious and the incidence of events leading to treatment
discontinuation was ≤ 0.5% for any of the adverse reactions listed above.

Tabulated list of adverse reactions

The adverse reactions observed in the placebo-controlled and uncontrolled phase 3 clinical studies in
patients (N = 1306) treated with difelikefalin are listed in Table 1 by MedDRA system organ class,
preferred term and frequency.

The frequency is classified as common (≥ 1/100 to < 1/10) and uncommon (≥ 1/1,000 to < 1/100).

Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Table 1: Adverse reactions attributed to the treatment with difelikefalin in haemodialysis
patients

1 Mental status changes included MedDRA preferred terms of confusional state and mental status changes.
2 Paraesthesia included MedDRA preferred terms of paraesthesia, hypoesthesia, paraesthesia oral and hypoesthesia oral.

Description of selected adverse reactions

Somnolence

Somnolence was reported as treatment emergent adverse event in 2.2% of subjects randomised to
difelikefalin. The vast majority of these events was mild or moderate in severity. In 0.3% of patients,
somnolence led to discontinuation of treatment with difelikefalin. Somnolence was reported as serious
adverse event in <0.1% of difelikefalin treated subjects. In 1.1% of patients, somnolence was reported
to have a causal relationship to difelikefalin treatment. Somnolence occurred within the first 3 weeks
of treatment and tended to subside with continued dosing.
The likelihood of somnolence may increase when difelikefalin is concomitantly used with other
medicinal products (see sections 4.4 and 4.5).

Dizziness

Dizziness was reported as treatment emergent adverse event in 7.9% of subjects randomised to
difelikefalin. The vast majority of these events was mild or moderate in severity. In 0.5% of patients,
dizziness led to discontinuation of treatment with difelikefalin. Dizziness was reported as serious
adverse event in 0.5% of difelikefalin treated subjects. In 0.9% of patients, dizziness was reported to
have a causal relationship to difelikefalin treatment. Dizziness occurred within the first 9 weeks of
treatment and was generally transient.
The likelihood of dizziness may increase when difelikefalin is concomitantly used with other
medicinal products (see sections 4.4 and 4.5).

Mental status changes

Mental status change (including confusional state) was reported as treatment emergent adverse event
in 4.4% of subjects randomised to difelikefalin.
The majority of these events was mild or moderate in severity. In less than 0.2% of patients, mental
status changes led to discontinuation of treatment with difelikefalin.
Mental status changes were reported as serious adverse event in 2.2% of difelikefalin treated subjects.
In 0.3% of patients, mental status changes were reported to have a causal relationship to difelikefalin
treatment.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions.

To report any side effect(s):
Saudi Arabia:
The National Pharmacovigilance and Drug Safety Centre (NPC)

• Fax: +966-11-205-7662
• Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.
• Toll free phone: 8002490000
• E-mail: npc.drug@sfda.gov.sa
• Website: www.sfda.gov.sa/npc

Single dose of difelikefalin up to 12 times and multiple doses of difelikefalin up to 5 times the clinical
dose of 0.5 micrograms/kg were administered in clinical studies in patients undergoing haemodialysis.
A dose-dependent increase in adverse events including dizziness, somnolence, mental status changes,
paraesthesia, fatigue, hypertension and vomiting, was observed.
In the event of overdose, the appropriate medical attention based on patient’s clinical status should be
provided. Haemodialysis for 4 hours using a high-flux dialyzer effectively cleared approximately
70-80% of difelikefalin from plasma, and difelikefalin was not detectable in plasma at the end of the
second of two dialysis cycles (see section 5.2).

Pharmacotherapeutic group: all other therapeutic products, other therapeutic products, ATC code:
V03AX04

Mechanism of action

Difelikefalin is a selective kappa opioid receptor agonist with low central nervous system penetration.
The physicochemical properties of difelikefalin (hydrophilic, synthetic D-amino acid peptide with
high polar surface area and charge at physiological pH) minimize its passive diffusion (permeability)
and active transport across membranes, thus limiting penetration into the central nervous system.
The pathophysiology of chronic kidney disease-associated pruritus is thought to be multifactorial,
including systemic inflammation and an imbalance in the endogenous opioid system (e.g.,
overexpression of mu opioid receptors and concomitant downregulation of kappa opioid receptors).
Opioid receptors are known to modulate itch signals and inflammation, with kappa opioid receptor
activation reducing itch and producing immunomodulatory effects.

The activation of kappa opioid receptors on peripheral sensory neurons and immune cells by
difelikefalin are considered mechanistically responsible for the antipruritic and anti-inflammatory
effects.

Clinical efficacy and safety

Placebo-controlled studies

In two pivotal clinical phase-3 studies of similar double-blind, randomised, placebo-controlled design
(KALM-1 and KALM-2), chronic kidney disease patients on haemodialysis with moderate-to-severe
pruritus received either placebo or 0.5 micrograms/kg difelikefalin intravenously 3 times a week
following haemodialysis for 12 weeks. A maximum of 4 doses per week was allowed in patients
receiving an additional dialysis during a given week. The primary endpoint in both studies was the
percentage of patients who achieved at least a 3-point reduction from baseline in the Worst
Itching-Numerical Rating Scale (WI-NRS) at 12 weeks. The main secondary endpoints in both studies
were the percentages of patients with an improvement in the WI-NRS of at least 4 points after
12 weeks and the changes in itch severity and itch-related quality of life (QoL) as measured by the
total Skindex-10 and the 5-D Itch scale. A responder analysis based on Patient Global Impression of
Change was also included.
A total of 851 patients with moderate-to-severe pruritus (baseline WI-NRS >4) were enrolled in the
pivotal studies. Mean age was 59 years, 33.1% were aged 65 and over and 11.1% were aged 75 and
over; 60% of patients were male. The baseline mean WI-NRS scores were 7.18 in both, difelikefalin
and placebo arms; baseline median WI-NRS scores were 7.13 (range 4.2 to 10) in difelikefalin and
7.13 (range 4.1 to 10) in placebo arm. Other disease characteristics at baseline were comparable in
difelikefalin and placebo arms: time from diagnosis of chronic kidney disease (8.22 years vs.
8.54 years), duration of pruritus (3.20 years vs. 3.31 years) and use of medicinal products intended to
relieve pruritus such as antihistamines, corticosteroids, gabapentin or pregabalin (37.5% vs. 38%).
Across studies, difelikefalin significantly reduced itch intensity and improved itch-related QoL over
12 weeks as shown in Table 2.

Table 2: Summary of primary and key secondary outcomes in KALM-1 and KALM-2 at week 12

1 Was not tested based on the hierarchical testing order.

Figure 1 shows the mean percentage from KALM-1 and KALM-2 with a ≥ 3-point improvement
from baseline in WI-NRS score by study week. Based on odds ratios, statistically significant
improvements favouring the difelikefalin group were seen by week 3 in KALM-1 and by week 2 in
KALM-2 and continued at each subsequent week through week 12 in both studies.

Figure 1: Percentage of patients with ≥ 3-point improvement with respect to WI-NRS score by
week in KALM-1 and KALM-2 (ITT population)
KALM-1

Open label extension studies

The effect of treatment with difelikefalin for up to 52 weeks was evaluated using the 5-D Itch Scale in
single arm, open label extensions of studies KALM-1 and KALM-2 including 712 patients.
In patients switching from placebo to difelikefalin at the end of the double-blind phase, an
improvement in 5-D Itch score was observed after 4 weeks of treatment, with an LS mean (SE) of the
change from baseline comparable to the patients receiving difelikefalin from study start: -6.0 (0.22) vs.
-5.7 (0.23). The improvement in 5-D Itch score was maintained in both treatment groups throughout
the 52-week treatment.

Paediatric population

The European Medicines Agency has deferred the obligation to submit the results of studies with
difelikefalin in one or more subsets of the paediatric population in the treatment of chronic kidney
disease associated pruritus (see section 4.2 for information on paediatric use).

In patients with severe renal impairment undergoing haemodialysis, total body clearance of
difelikefalin is reduced compared to healthy subjects and plasma concentrations decrease slowly until
cleared during dialysis. Due to the 70-80% of difelikefalin removed during dialysis, difelikefalin is
administered after each haemodialysis session in these patients. The available data on interindividual
variability in haemodialysis subjects receiving 0.5 microgram/kg difelikefalin suggest that variability
of AUC can exceed 30%.

Distribution

Plasma protein binding of difelikefalin is low to moderate, ranging from 24-32%, and remains
unaffected by renal impairment. Mean volume of distribution at steady state ranged from 145 to
189 mL/kg in healthy subjects and from 214 to 301 mL/kg in haemodialysis patients with
moderate-to-severe pruritus. Difelikefalin penetration into the central nervous system is limited (below
limit of quantification) as shown by physico-chemical, in-vitro and animal data.

Elimination

In healthy subjects, the primary route of elimination for difelikefalin is renal, accounting for about
81% of the dose being excreted in urine as compared to 11% via faecal excretion. In both healthy
volunteers and subjects on haemodialysis, most of the dose excreted into urine and faeces was
unchanged difelikefalin with minor quantities of putative metabolites, none exceeding 2.5%. Mean
total clearance ranged from 54 to 71 mL/h/kg and mean half-lives from 2 to 3 hours. By contrast, in
renally impaired haemodialysis patients, elimination was predominantly via faeces, accounting on
average for about 59% of the dose; about 19% were recovered in dialysate and about 11% were found
in urine. As compared to subjects with normal renal function, mean total clearance decreased and
half-lives increased about 10-fold with ranges of 5.3 to 7.5 mL/h/kg and 23 to 31 hours, respectively.

Interaction with other medicinal products

Difelikefalin is neither a substrate for CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or
CYP3A4, nor an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or
CYP3A4/5 and has minimal to no potential for induction of human CYP1A2, CYP2B6, or CYP3A. It
is not an inhibitor of glucuronidation enzymes either (UGT1A3, UGT1A9, or UGT2B7).
In addition, difelikefalin is not an inhibitor of BCRP, BSEP, LAT1, MATE1, MATE2-K, MRP2,
OAT1, OAT3, OATP1A2, OATP1B1, OATP1B3, OCT1, OCT2, OCT3, P-glycoprotein, PEPT1 or
PEPT2, and is not a substrate for ASBT, BCRP, BSEP, LAT1, MATE1, MATE2-K, MRP2, OAT1,
OAT2, OAT3, OATP1A2, OATP1B1, OATP1B3, OATP2B1, OCT1, OCT2, OCT3, OCTN1,
OCTN2, OSTαβ, P-glycoprotein, PEPT1 or PEPT2.

Linearity/non-linearity

Pharmacokinetics of difelikefalin were demonstrated to be linear and dose-proportional in healthy
subjects (tested over dose ranges of 1 to 40 and 1 to 20 micrograms/kg in single and repeated dose
studies, respectively). Steady state dose proportionality was also established in chronic kidney disease
patients on haemodialysis receiving repeated doses from 0.5 to 2.5 micrograms/kg, 3 times per week
for 1 week. However, in another study dose proportionality was observed at doses of 0.5 and
1 micrograms/kg, but not at the dose of 1.5 micrograms/kg. Trough plasma concentration values
reached steady state by the second dose and for the dose of 0.5 micrograms/kg, mean accumulation
ratio was 1.144 in one study based on AUC0-48h and 1.33 in another study, based on AUC0-44h; showing
that variability for accumulation parameters can exceed 30%.

Characteristics in specific groups of subjects or patients

Based on available evidence, there is no indication that factors such as age, sex, ethnicity, or mild to
moderate hepatic impairment have any impact on the pharmacokinetics of difelikefalin.

Non-clinical data reveal no special hazard for humans based on conventional studies of safety
pharmacology, repeat-dose toxicity, genotoxicity and carcinogenic potential.

Reproductive toxicity

In rats, male and female fertility, early embryonic, and prenatal and postnatal development were not
affected up to 2000-fold the human AUC. In the rabbit, prenatal development was neither impaired
despite marked maternal toxicity at 30-fold the human AUC.

Difelikefalin crosses the placenta in rats.

Abuse and dependence potential

The abuse and dependence potential studies in the rat suggest that difelikefalin is not likely to present
a risk of physical dependence or abuse potential.

Acetic acid (for pH adjustment)
Sodium acetate trihydrate (for pH adjustment)
Sodium chloride
Water for injections

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal
products.

This medicinal product does not require any special storage conditions.

Korsuva is supplied in a single use 2 mL glass vial (type I), with a bromobutyl rubber stopper, an
aluminium seal and a blue flip-off plastic cap.

Pack sizes of 3 and 12 vials containing 1 mL of solution for injection.
Not all pack sizes may be marketed.

For single use only.

Any unused medicinal product or waste material should be disposed of in accordance with local
requirements